Adaptogen herbal extract

Ashwagandha (KSM-66)

Ashwagandha (KSM-66): the app lists a half-life of about 6 hours, while a single-dose study of a different root extract reported 1.696 to 4.377 hours for four bioactive constituents.1

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Ashwagandha (KSM-66) after one dose: 50% at ~6 h, 25% at 12 h, 12.5% at 18 h.

Drawn from the half-life in the app's model, ~6 h. The model's figures

Chandrasekhar and colleagues describe the KSM-66 extract used in their 2012 trial as drawn "only from the roots of the Ashwagandha plant, using no other parts like leaves" and standardized to a withanolide content of at least 5% by HPLC.2 The same paper calls it a "high-concentration full-spectrum" extract and states that it was provided by Ixoreal Biomed, Hyderabad, India.2 The app lists it as an adaptogen supplement taken by mouth, with typical doses of 300–600 mg/day.

In each of the six KSM-66 studies described below, the extract came from Ixoreal Biomed.2,3,4,5,6,7 The controlled KSM-66 trials enrolled 50 to 64 adults, and the longest study is an observational cohort of 191 adults followed for 12 months.4,2,7 The app grades the evidence for this compound as strong; that grade is the app's own and is not a finding of these studies.

2

How it works

Chandrasekhar and colleagues introduce adaptogens as "herbs that improve an individual's ability to cope with stress", and their trial measured serum cortisol and stress questionnaires rather than a molecular pathway.2 Wankhede and colleagues write that "several mechanisms of action" could have contributed to their strength and recovery results, including testosterone, cortisol, energy production and antioxidant effects.3

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~6 h
Bioavailability
95%
Typical dose
300–600 mg/day
Route
Oral
Time to peak
~2 h

The second column of the table holds the app's own figures, and the third holds what the sources report in people. Among the 5 PubMed records returned for a query on Withania somnifera pharmacokinetics in humans, the two single-dose studies of plasma withanolides used root extracts other than KSM-66, and the searches run for this review did not return a human pharmacokinetic study of KSM-66 itself.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-lifeAbout 6 hoursHalf-lives of 1.696 to 4.377 hours across four bioactive constituents after 400 mg of a root extract with a stated 2.5% total withanolides (a different extract from KSM-66), with the range differing for each constituent1. The Vaidya summary calls the half-life "optimum" for a different extract and gives no figure for it8
BioavailabilityAbout 95%No percentage is given in the sources cited here; the Vaidya summary states only that the constituents "have high oral bioavailability" after a 500 mg single dose of a different extract8
Time to peakAbout 2 hoursMean times to maximum concentration of 0.903 to 1.639 hours across four constituents in 18 healthy men after 500 mg8, and 1.000 to 1.416 hours across four constituents after 400 mg1, both for extracts other than KSM-66
RouteOralBoth pharmacokinetic studies gave capsules by mouth8,1

Deeper analysis: the two single-dose pharmacokinetic studies

Vaidya and colleagues (Journal of Ethnopharmacology, 2024) gave 18 healthy men aged 18 to 45 a single 500 mg dose of a root extract sold under the names AgeVel and Witholytin, which contained "not less than 7.5 mg of total withanolides", and measured five constituents in plasma.8 Mean maximum concentrations were 0.639, 2.926, 2.833 and 5.498 ng/mL for withanoside IV, withanolide A, withaferin A and 12-deoxy-withastramonolide, and withanoside V was detected but below the lower limit of quantification.8 The authors report no adverse reaction at 500 mg, the design was non-randomized and single-dose in men only, and eight of the eleven listed authors are affiliated with Pharmanza Herbal Pvt. Ltd., while the competing-interest statement declares none.8 Sharma and colleagues (Drug Metabolism and Personalized Therapy, 2025) gave healthy male and female volunteers two 200 mg capsules of an extract with a stated 2.5% total withanolides and reported Cmax of 0.472 to 4.468 ng/mL, Tmax of 1.000 to 1.416 hours and an elimination half-life that "differed for each bioactive".1 The authors state that participants "reported normal physical, hematological, and biochemical parameters", and the author list includes affiliations to Phytoveda Pvt. Ltd. and Viridis Biopharma Pvt. Ltd.1 Only the PubMed record of each study was available, so the number of participants in the Sharma study, the extract brand and the authors' own stated limitations are not reported here. A registered pharmacokinetic study in older adults (Oregon Health and Science University, funded in part by the National Center for Advancing Translational Sciences) tested Shoden, "dried 70% ethanolic extract of Withania somnifera (ashwagandha, WS) root and leaf, standardized to 35% withanolide glycosides", at 240 and 480 mg.9 The registry lists the status as terminated because the "Amended study protocol was not reapproved in time for completion of study activities", and sufficient samples for pharmacokinetic curves were collected for two participants at 240 mg and three at 480 mg.9

4

Human studies

Table 4.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
Chandrasekhar and colleagues, Indian Journal of Psychological Medicine 20122Single-centre, double-blind, randomised, placebo-controlled; no support stated (Source of Support: Nil)64 adults with a history of chronic stress, aged 18 to 54; 61 in the efficacy analysis300 mg extract capsule twice daily for 60 daysPerceived Stress Scale fell 44.0% against 5.5% on placebo; serum cortisol fell 27.9% against 7.9%; six adverse effects with ashwagandha, five with placebo, no serious adverse events
Wankhede and colleagues, Journal of the International Society of Sports Nutrition 201538-week, randomised, double-blind, placebo-controlled, with resistance training in both groups57 men aged 18 to 50 with little resistance-training experience, randomised 29 to ashwagandha and 28 to placebo300 mg extract twice daily for 8 weeksBench-press strength rose 46.0 kg against 26.4 kg (p = 0.001) and leg-extension 14.5 kg against 9.8 kg (p = 0.04); thigh size did not differ (p = 0.36); testosterone rose 96.2 against 18.0 ng/dL (p = 0.004); no serious side effects in either group
Choudhary and colleagues, Ayu 20154Prospective, double-blind, randomised, placebo-controlled50 healthy athletic adults of both sexes; 49 analysed after one withdrawal300 mg extract twice daily for 12 weeksMean VO2 max, estimated from a 20-m shuttle run test, rose 4.91 with ashwagandha (n = 24) against 1.42 with placebo (n = 25) at 8 weeks and 5.67 against 1.86 at 12 weeks; no change in resting pulse, blood pressure or respiration in either group
Choudhary and colleagues, Journal of Evidence-Based Complementary and Alternative Medicine 20175Double-blind, randomised, placebo-controlled; principal investigator's organisation provided support52 adults under chronic stress300 mg extract twice daily for 8 weeksAuthors report significant improvements in the primary (Perceived Stress Scale, Food Cravings Questionnaire) and secondary measures; serum cortisol fell from baseline by 16.05% at 4 weeks and 22.2% at 8 weeks in the ashwagandha group, with the difference in reduction against placebo significant at both points (P = .0328, P = .0019); weight fell 3.03% against 1.46% on placebo at 8 weeks (P = .0148); three food-craving components did not differ from placebo; 2 of 52 (4%) reported adverse effects
Salve and colleagues, Cureus 201968-week, randomised, double-blind, placebo-controlled, three arms in a 1:1:1 ratio60 adults with a baseline Perceived Stress Scale score above 20; 58 completed125 mg or 300 mg twice daily (250 or 600 mg/day), or placebo, for 8 weeksPerceived Stress Scale at week 8: 15.00 (250 mg/day), 14.15 (600 mg/day), 16.63 (placebo), from baselines of 22.65, 22.95 and 22.70; anxiety scale change not significant against placebo at 250 mg/day; adverse-event data available for 58 participants, none reported
Salve and colleagues, Phytotherapy Research 20267,10Prospective, multicentre, observational; no placebo group; no specific funding191 adults aged 18 to 65300 mg extract twice daily, registered, for 12 months18 mild adverse events, nausea the most frequent (6, 3.1%); alanine transaminase 31.31 at baseline and 33.68 IU/L at the end; cortisol fell and testosterone rose

Deeper analysis: Chandrasekhar 2012, stress and cortisol

Chandrasekhar and colleagues at Asha Hospital, Hyderabad, randomised 64 adults with chronic stress, 32 to each arm, and 3 (two on ashwagandha, one on placebo) were lost to follow-up.2 Efficacy was analysed in the 61 who complied with the protocol, and safety in all 64.2 The paper's summary reports serum cortisol as reduced "(P=0.0006)" against placebo, while the results text gives P=0.002 for the difference in the reduction on day 60 and P=0.006 for the difference in average levels.2 Laboratory values were unchanged except serum globulin and triglycerides, which the authors call "clinically insignificant".2 The reported adverse effects with ashwagandha were nasal congestion, constipation, cough and cold, drowsiness and decreased appetite, and the authors call all adverse events "mild in nature".2 The authors state that the sample size "was not very large", that none of the enrolled subjects had a psychological or other systemic illness, and that studies of longer duration are needed.2 The paper lists "Source of Support: Nil" and "Conflict of Interest: None", and the extract was provided by Ixoreal Biomed.2

Deeper analysis: Wankhede 2015, strength and recovery

Wankhede and colleagues randomised 57 men to 300 mg of extract twice daily or starch placebo for 8 weeks of resistance training, with muscle strength on bench press and leg extension as the primary measure and muscle size, body composition, serum testosterone and creatine kinase as secondary measures.3 Strength and size rose in both groups because both trained, and the question was whether the gain was larger with ashwagandha.3 The post-intervention testosterone level was 726 against 693 ng/dL in the text, which the authors describe as "not detectable as statistically significantly different".3 The paper's summary describes 57 randomised participants, the result tables list 25 per group and the limitations refer to "the sample size of 50"; the text does not say why 7 were not analysed.3 The authors name three limitations: "the subjects are untrained and moderately young, the sample size of 50 is not large and the study period is of duration only 8 weeks".3 The authors declare no conflict of interests, thank Shri Kartikeya Pharma and Ixoreal BioMed for supplying the KSM-66 extract, and the article carries no separate funding statement.3

Deeper analysis: Salve 2019, two doses against placebo

Salve and colleagues compared 250 mg/day and 600 mg/day of KSM-66 with placebo in 60 stressed adults, and the paper's summary describes it as the first study to use a high-concentration root extract while also varying the dosage substantially.6 At week 8 the Perceived Stress Scale mean was 15.00 at 250 mg/day, 14.15 at 600 mg/day and 16.63 on placebo, and serum cortisol and sleep quality also differed from placebo at both doses.6 The lower dose did not separate from placebo on the Hamilton Anxiety Rating Scale, and the authors write that the 250 mg/day group was "not as effective as" the 600 mg/day group on the stress scale.6 The paper reports no adverse events and lists no funding source in the text read, the authors declare no competing interests, and the extract was gifted by Ixoreal Biomed.6 The authors' stated limitations call for a larger and wider cross-section of participants and a longer duration.6

Deeper analysis: Salve 2025, 12-month safety cohort

Salve and colleagues followed 191 adults on KSM-66 for 12 months in a prospective observational study registered as NCT06244147, with adverse events as the primary outcome and liver, renal, thyroid, cortisol and testosterone laboratory measures at 6 and 12 months.7,10 All 18 adverse events were of mild severity (grade 1), the most frequent were nausea in 6 patients (3.1%), abdominal pain (1.6%) and headache (1.6%), and diarrhoea, dizziness and vomiting were each reported by 2 patients (1.0%).7 The paper also states that one participant reported dizziness and was advised to take appropriate concomitant medication.7 Alanine transaminase was 31.31 IU/L at baseline and 33.68 IU/L at the end, and aspartate transaminase was 30.61 and 29.02 IU/L.7 Free testosterone rose 13.8% and total testosterone 15.1% in men and women together, with no placebo comparison.7 The authors list a "relatively small sample size (n = 191)", which "limits the ability to detect the rare or idiosyncratic adverse effects", and note that "the observational study design limits causal inference, and no placebo control was used".7 The paper reports no specific funding and no conflicts, the product was obtained from Ixoreal Biomed, and two of the seven authors are affiliated with the San Francisco Research Institute, whose registry name, SF Research Institute, Inc., is also the registered sponsor.7,10

Other trials and pooled analyses

The registry description says 200 subjects will be included and lists an enrollment count of 200 (type ACTUAL), against 191 in the paper.10 Lopresti and colleagues (American Journal of Men's Health, 2019) enrolled 57 overweight men aged 40 to 70, of whom 50 completed the first 8-week period and 43 completed all 16 weeks, and gave them an extract called Shoden, not KSM-66, in a crossover design, with Arjuna Natural Ltd. funding the project; the authors state it was not involved in the design of the research, analysis of data or writing of the report.11 They report an 18% greater increase in salivary DHEA-S and a 14.7% greater increase in salivary testosterone than placebo, and no significant between-group differences in cortisol, estradiol, fatigue, vigor or sexual well-being.11 Their stated limitations include a small sample, recruitment through social media and lifestyle changes that were not adequately monitored.11 Arumugam and colleagues (Explore, 2024) pooled nine randomised trials of ashwagandha formulations in 558 patients, without restriction to KSM-66, and reported mean differences against placebo of -4.72 on the Perceived Stress Scale, -2.19 on the Hamilton Anxiety Scale and -2.58 for serum cortisol.12 They state that four of the included studies reported mild to moderate adverse events and that "further information is required to determine its safety with long-term administration"; only the PubMed record was available, so per-trial brands, funding and risk of bias are not reported here.12

5

Doses reported in studies and on labels

Table 5.1Doses reported in studies and on labels7 rows
SourceDose and routeComparatorLength and n
Chandrasekhar 20122One 300 mg extract capsule twice daily, oralPlacebo capsules60 days; 64 enrolled
Wankhede 20153300 mg root extract twice daily, oralStarch placebo8 weeks; 57 randomised
Choudhary 20154One 300 mg capsule twice daily, oralSucrose placebo capsules12 weeks; 50
Choudhary 20175300 mg twice daily, oralPlacebo8 weeks; 52
Salve 20196125 mg or 300 mg twice daily (250 or 600 mg/day), oralIdentical placebo8 weeks; 60 enrolled, 58 completed
Salve 2026 and NCT0624414710,7300 mg twice daily, oral, as registeredNone (single-arm cohort)12 months; 191 analysed, 200 registered
Liver injury case series, Björnsson 202013Daily doses of 450 to 1350 mg of ashwagandha products, from label informationNone (case series of 5 patients)Onset after 2 to 12 weeks

No prescribing label for a single-ingredient KSM-66 product was identified: a DailyMed search for "ashwagandha" returned four records, and none of their titles names KSM-66. The app's typical dose range is 300–600 mg/day; the KSM-66 trials above all included 600 mg/day, Salve 2019 also tested 250 mg/day, and none tested 300 mg/day.

In Chandrasekhar 2012 there were six adverse effects on ashwagandha and five on placebo, with no serious adverse events, and the authors state that the difference was not statistically significant.2 In Choudhary 2017, 2 of 52 participants (4%) reported giddiness, heaviness of head, blurring of vision or hyperacidity, which the authors call "mild and temporary", and 96% in each group rated tolerability "excellent".5 In the 12-month cohort, 18 of 191 participants reported adverse events, all grade 1 and resolved without intervention, with nausea the most frequent.7 Björnsson and colleagues (Liver International, 2020) described five patients with liver injury attributed to ashwagandha-containing supplements, three in Iceland in 2017 to 2018 and two from the US Drug-Induced Liver Injury Network in 2016.13 All five developed jaundice and symptoms such as nausea, lethargy, pruritus and abdominal discomfort after 2 to 12 weeks, the injury was cholestatic or mixed, no patient developed hepatic failure, and liver tests normalised within 1 to 5 months in four patients while one was lost to follow-up.13 The paper grades the severity as moderate in all five cases and reports that one patient was hospitalized.13 The authors note that four patients were consuming additional supplements and that in one case rhodiola "was a possible causative agent along with ashwagandha", and they conclude that the cases "illustrate the hepatotoxic potential of ashwagandha".13 The three Icelandic cases involved one product from one manufacturer, no rechallenge was performed, and the full text does not identify any product as KSM-66; the authors declare no conflicts of interest and the work was supported by US National Institutes of Health grants.13

7

Bloodwork and markers

Sources in this part

  1. 7Salve et al., 2026

The app lists no markers to monitor for this compound; the markers reported in the studies are serum cortisol, testosterone, liver enzymes and creatine kinase. In the 12-month cohort, mean alanine transaminase moved from 31.31 to 33.68 IU/L and aspartate transaminase from 30.61 to 29.02 IU/L, which the authors describe as showing no clinically significant change.7

The European Medicines Agency's herbal committee (HMPC) adopted a public statement on 9 July 2013 that a Community herbal monograph on Withania somnifera root "cannot be established at present".14 It gave two reasons: it had "not been able to find adequate evidence allowing a description of the herbal preparations", and not enough evidence of at least 30 years of medicinal use including at least 15 years in the European Union.14 The statement concerns traditional herbal medicinal products and does not assess KSM-66 or any other named extract.14 A 2024 commentary by Patwardhan and colleagues states that the Danish Veterinary and Food Administration "decided to ban Ashwagandha based on a 2020 report" by the Technical University of Denmark.16 That commentary criticises the report, saying that it "does not seem to be peer-reviewed", and its competing-interest statement notes that three authors are involved in ashwagandha research and one has an honorary association with the World Ashwagandha Council.16 The Danish report itself could not be retrieved from the address found, so the ban's scope and current status are taken from this commentary only. A search of the text of the WADA 2026 Prohibited List for "ashwagandha" and "Withania" returned no match, and the list states that it "shall come into effect on 1 January 2026".15 That search covers the plant names only; it does not address individual constituents or the contents of any product.

No pharmacokinetic study of KSM-66 itself was identified in the PubMed and ClinicalTrials.gov results searched, so the app's 6 h half-life, 95% bioavailability and 2 h time to peak have no KSM-66-specific figure beside them here. The sources cited give no figure for the 12-hour duration of activity that the app lists. The six KSM-66 studies described used extract from one supplier, enrolled 50 to 64 adults in the controlled trials, ran 8 to 12 weeks, and the sources describe them as small; the longest follow-up is 12 months, in a cohort without a placebo group.5,4,7 Whether the liver injury cases involve KSM-66, how often such injury occurs, and whether the 12-month cohort's laboratory results would hold in a placebo-controlled design are not answered by the sources cited.13,7

What is the half-life of ashwagandha (KSM-66)?

The app lists a half-life of about 6 hours, while a single-dose study of a different root extract reported 1.696 to 4.377 hours across four bioactive constituents.1 No half-life figure for KSM-66 itself appeared in the PubMed and ClinicalTrials.gov results searched.

How long does ashwagandha take to reach its peak level?

The app lists about 2 hours, while single-dose studies of other root extracts reported mean times to maximum concentration of 0.903 to 1.639 hours and 1.000 to 1.416 hours for individual withanolides.8,1

Is ashwagandha banned by WADA?

A search of the text of the WADA 2026 Prohibited List for "ashwagandha" and "Withania" returned no match.15 The list is effective from 1 January 2026, and the search covers the plant names only, not constituents or product contents.15

What is KSM-66 ashwagandha?

KSM-66 is a root-only extract of Withania somnifera that Chandrasekhar and colleagues describe as standardized to at least 5% withanolides by HPLC.2

Has ashwagandha been linked to liver injury?

Björnsson and colleagues described five patients with liver injury attributed to ashwagandha-containing supplements, and concluded that the cases "illustrate the hepatotoxic potential of ashwagandha".13 A 12-month cohort of 191 adults on KSM-66 reported no clinically significant change in alanine or aspartate transaminases, but it had no placebo group and the authors say its size limits detection of rare adverse effects.7

Does KSM-66 ashwagandha lower cortisol?

In Chandrasekhar 2012, serum cortisol fell 27.9% from baseline with KSM-66 against 7.9% with placebo over 60 days in the 61 adults with chronic stress included in the efficacy analysis, out of 64 enrolled.2 Choudhary 2017 reported reductions from baseline of 16.05% at 4 weeks and 22.2% at 8 weeks in the ashwagandha group, with the difference in reduction against placebo significant at both points, and the Lopresti trial of a different extract reported no significant between-group difference in cortisol.5,11

Does ashwagandha raise testosterone?

In Wankhede 2015, testosterone rose 96.2 ng/dL with KSM-66 against 18.0 ng/dL with placebo (p = 0.004) in men in resistance training (57 randomised, 25 per group in the result tables), though the post-intervention levels were not significantly different.3 The 14.7% greater testosterone increase in overweight men aged 40 to 70 came from a trial of a different extract, Shoden, funded by its maker, Arjuna Natural Ltd.11

What side effects were reported in KSM-66 trials?

In the 12-month cohort of 191 adults, 18 mild adverse events were reported, with nausea the most frequent at 6 patients (3.1%).7 In Chandrasekhar 2012 there were six adverse effects on ashwagandha and five on placebo, and in Salve 2019 no adverse events were reported.2,6

Is ashwagandha approved as a herbal medicine in the EU?

The EMA herbal committee stated in 2013 that a Community herbal monograph on Withania somnifera root "cannot be established at present".14 It cited insufficient extract specification and insufficient evidence of 30 years of medicinal use, and the statement concerns a Community herbal monograph on traditional herbal medicinal products.14

Is ashwagandha banned in Denmark?

A 2024 commentary states that the Danish Veterinary and Food Administration decided to ban ashwagandha based on a 2020 report by the Technical University of Denmark.16 The commentary's authors include researchers in ashwagandha research and criticise the report, and the Danish report itself was not retrievable.16

12

References

  1. Sharma E, et al. An open-label, single dose, safety and pharmacokinetic study of Withania somnifera root extract in healthy volunteers. Drug Metab Pers Ther 2025. PMID 39963957
  2. Chandrasekhar K, et al. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med 2012. PMID 23439798
  3. Wankhede S, et al. Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial. J Int Soc Sports Nutr 2015. PMID 26609282
  4. Choudhary B, et al. Efficacy of Ashwagandha (Withania somnifera [L.] Dunal) in improving cardiorespiratory endurance in healthy athletic adults. Ayu 2015. PMID 26730141
  5. Choudhary D, et al. Body Weight Management in Adults Under Chronic Stress Through Treatment With Ashwagandha Root Extract: A Double-Blind, Randomized, Placebo-Controlled Trial. J Evid Based Complementary Altern Med 2017. PMID 27055824
  6. Salve J, et al. Adaptogenic and Anxiolytic Effects of Ashwagandha Root Extract in Healthy Adults: A Double-blind, Randomized, Placebo-controlled Clinical Study. Cureus 2019. PMID 32021735
  7. Salve J, et al. Safety of 12-Months Administration of Ashwagandha (Withania somnifera) Standardized Root Extract in Healthy Adults: A Prospective, Observational Study. Phytother Res 2026. PMID 41063394
  8. Vaidya VG, et al. Clinical pharmacokinetic evaluation of Withania somnifera (L.) Dunal root extract in healthy human volunteers: A non-randomized, single dose study utilizing UHPLC-MS/MS analysis. J Ethnopharmacol 2024. PMID 38122911
  9. Oregon Health and Science University. Ashwagandha Pharmacokinetics Study in Older Adults. ClinicalTrials.gov NCT06171724. NCT06171724
  10. SF Research Institute, Inc. Long Term Safety and Efficacy of KSM-66 Ashwagandha in Adults. ClinicalTrials.gov NCT06244147. NCT06244147
  11. Lopresti AL, et al. A Randomized, Double-Blind, Placebo-Controlled, Crossover Study Examining the Hormonal and Vitality Effects of Ashwagandha (Withania somnifera) in Aging, Overweight Males. Am J Mens Health 2019. PMID 30854916
  12. Arumugam V, et al. Effects of Ashwagandha (Withania Somnifera) on stress and anxiety: A systematic review and meta-analysis. Explore (NY) 2024. PMID 39348746
  13. Björnsson HK, et al. Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network. Liver Int 2020. PMID 31991029
  14. European Medicines Agency, HMPC. Public statement on Withania somnifera (L.) Dunal, radix. EMA/HMPC/681519/2012, 9 July 2013. EMA public statement
  15. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
  16. Patwardhan B, et al. Danish ban on Ashwagandha: Truth, evidence, ethics, and regulations. J Ayurveda Integr Med 2024. PMC11403136